Composition and method for treating alzheimer's disease
AssigneeEisai R&D Management Co., Ltd.
InventorsAndrew Satlin, Tatsuto FUKUSHIMA
Life of this patent
Estimating the term…
Abstract
Methods and combination therapties for treating, preventing, and/or delaying the onset and/or development of Alzheimer's disease using an anti Aβ protofibril (such as, for example, BAN2401) and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1-,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof (Compound X) are provided.
Claims12
A method of treating Alzheimer's disease comprising administering to a subject in need thereof a therapeutically effective amount of an anti-A3 protofibril antibody and a therapeutically effective amount of N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof,
- wherein the antibody comprises (a) a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:1 and (b) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:2,
- wherein the antibody is administered at a dose ranging from 2.5 mg/kg to 10 mg/kg,
- wherein N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide and/or a pharmaceutically acceptable salt thereof is administered at a dose ranging from 5 mg/day to 50 mg/day.
A pharmaceutical composition for use in treating of Alzheimer's disease comprising an anti-AP protofibril antibody and N-[3-((4aS,5R,7aS)-2-amino-5-methyl-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl]-5-difluoromethylpyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof,
- wherein the antibody comprises (a) a heavy chain variable domain comprising an amino acid sequence of SEQ ID NO:1 and (b) a light chain variable domain comprising an amino acid sequence of SEQ ID NO:2.
Dependencies are inferred from the claim text.